Alistipes indistinctus

BacteriaBacteroidotaBacteroidiaBacteroidalesRikenellaceaeAlistipes
MCA-BAC-000050
TaxID: 626932 | Rank: species
Biology & Ecology
Biology
Gram Statusgram-negative
Oxygen Toleranceobligate anaerobe
Morphologybacillus (rod)
Ecology
Primary Nichesgut
Reservoirhuman
Metabolites

No metabolite relationships documented for this taxon.

Clinical Profile
Pathobiont
yes no context dependent unknown
Clinical Rolesprotective commensal
Typical Specimenstool
Risk ContextsNSCLC patients receiving PD-1/PD-L1 blockade
Clinical Associations:
E2
E3 — Strong human clinical evidence E2 — Moderate human evidence E1 — Limited / preliminary
Alistipes indistinctus was significantly enriched in NSCLC and RCC patients with longer progression-free survival (>3 months) vs. shorter PFS after PD-1/PD-L1 blockade, identified by shotgun metagenomics of pre-treatment stool (n=100) as one of several commensals overrepresented in responders.
PMID: 29097494
D002289 Carcinoma, Non-Small-Cell Lung D000082082 Immune Checkpoint Inhibitors H00014 Non-small cell lung cancer H00021 Renal cell carcinoma
E1
E3 — Strong human clinical evidence E2 — Moderate human evidence E1 — Limited / preliminary
Oral gavage with Alistipes indistinctus reversed compromised PD-1 blockade efficacy in antibiotic-treated mice receiving NR-FMT-induced dysbiosis bearing MCA-205 sarcomas, restoring antitumor effects comparable to those of A. muciniphila supplementation (Fig. 4C).
PMID: 29097494
D000082082 Immune Checkpoint Inhibitors D009369 Neoplasms
Last reviewed: 2026-04-03
Evidence Timeline
Related Taxa Shared Niche = same body site   Shared Risk = same vulnerable population